NCT04836195View on ClinicalTrials.gov

Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 14, 2021

Primary Completion Date

October 28, 2024

Study Completion Date

October 28, 2024

Conditions
B-cell Non Hodgkin LymphomaAdvanced Solid Tumor
Interventions
DRUG

PCLX-001 - 20mg

20mg daily oral pills

DRUG

PCLX-001 - 40mg

40mg daily oral pills

DRUG

PCLX-001 - 70mg

70mg daily oral pills

DRUG

PCLX-001 - 100mg

100mg daily oral pills

DRUG

PCLX-001 - 140mg

140mg daily oral pills

DRUG

PCLX-001 - 210mg

210mg daily oral pills

DRUG

PCLX-001 - 280mg

280mg daily oral pills

Trial Locations (4)

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z4E6

BC Cancer - Vancouver, Vancouver

M5G 2M9

Princess Margaret Hospital, Toronto

H2X 0A9

CR Centre Hospitalier de l'Université de Montréal - CHUM, Montreal

Sponsors
All Listed Sponsors
lead

Pacylex Pharmaceuticals

INDUSTRY

NCT04836195 - Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma | Biotech Hunter | Biotech Hunter